Literature DB >> 11849794

Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study.

Jacob Locke1, William Ellis, Kent Wallner, William Cavanagh, John Blasko.   

Abstract

PURPOSE: We prospectively investigated prognostic factors for men undergoing transperineal radioactive seed implantation for prostate cancer at the University of Washington. METHODS AND MATERIALS: Between February and April, 1998, 62 consecutive unselected patients were prospectively followed after brachytherapy for early-stage prostate adenocarcinoma. Pretreatment variables included age, American Urological Association (AUA) score, uroflowimetry, and prostate volume by ultrasound. Nonrandomized variables included hormonal therapy, seed type, and use of pelvic radiotherapy. Patients were contacted by phone at one week postoperatively and at one-month intervals thereafter. Follow-up continued until all patients provided the date of last catheterization.
RESULTS: Urinary retention rate at one week was 34% (21 of 63 patients). At one month, 29%; at three months, 18%; and at six months, 10%. Preoperative flow rate and post-void residual did not predict for retention (p =.48 and p =.58). Use of alpha blockers, hormonal therapy, type of seed (103Pd or 1251), or external beam radiotherapy had no impact on risk of retention at any followup point. Preimplant volume and AUA score predicted for retention on univariate analysis, but on multivariate analysis only postimplant volume remained significant (p =.02) for predicting retention risk and duration.
CONCLUSION: Patients with large prostate size (>36 g) and higher AUA score (>10) appear to be at greater risk of risk of retention as well as duration of retention as defined in our study. Further investigation will be needed to clarify the risk of urinary retention for men undergoing brachytherapy.

Entities:  

Mesh:

Year:  2002        PMID: 11849794     DOI: 10.1016/s0360-3016(01)02657-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds.

Authors:  V Morillo; J L Guinot; I Tortajada; J V Ricós; L Arribas; M Maroñas; M Estornell; J Casanova
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

2.  Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study.

Authors:  Nobutaka Shimizu; Takafumi Minami; Koichi Sugimoto; Yoshitaka Saito; Yutaka Yamamoto; Taiji Hayashi; Hidenori Tsuji; Masahiro Nozawa; Kazuhiro Yoshimura; Tokumi Ishii; Hirotsugu Uemura; Kiyoshi Nakamatsu
Journal:  World J Urol       Date:  2014-01-17       Impact factor: 4.226

3.  Does robotic technology mitigate the challenges of large prostate size?

Authors:  Ted A Skolarus; Ryan C Hedgepeth; Yun Zhang; Alon Z Weizer; Jeffrey S Montgomery; David C Miller; David P Wood; Brent K Hollenbeck
Journal:  Urology       Date:  2010-08-13       Impact factor: 2.649

Review 4.  Brachytherapy with permanent seed implantation.

Authors:  Shiro Saito; Hirohiko Nagata; Michio Kosugi; Kazuhito Toya; Atsunori Yorozu
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

5.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

6.  Prostate volume changes during permanent seed brachytherapy: an analysis of intra-operative variations, predictive factors and clinical implication.

Authors:  Ciprian Chira; Guila Delouya; Sandra Larrivée; Jean-Francois Carrier; Daniel Taussky
Journal:  Radiat Oncol       Date:  2013-07-09       Impact factor: 3.481

7.  Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer.

Authors:  Connor Chevli; Ramkishen Narayanan; Lisa Rambarran; Gregory Kubicek; K Kent Chevli; Michael Duff
Journal:  Res Rep Urol       Date:  2013-01-14

8.  Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).

Authors:  Einsley Janowski; Leonard N Chen; Joy S Kim; Siyuan Lei; Simeng Suy; Brian Collins; John Lynch; Anatoly Dritschilo; Sean Collins
Journal:  Radiat Oncol       Date:  2014-11-15       Impact factor: 3.481

9.  Current status of brachytherapy for prostate cancer.

Authors:  Dong Soo Park
Journal:  Korean J Urol       Date:  2012-11-14

10.  Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series.

Authors:  Yonina R Murciano-Goroff; Luciant D Wolfsberger; Arti Parekh; Fiona M Fennessy; Kemal Tuncali; Peter F Orio; Thomas R Niedermayr; W Warren Suh; Phillip M Devlin; Clare Mary C Tempany; Emily H Neubauer Sugar; Desmond A O'Farrell; Graeme Steele; Michael O'Leary; Ivan Buzurovic; Antonio L Damato; Robert A Cormack; Andriy Y Fedorov; Paul L Nguyen
Journal:  Radiat Oncol       Date:  2014-09-09       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.